BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Envafolimab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Envafolimab\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05024214-994@assetmemo.bio
DTSTAMP:20261121T004018Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Envafolimab: Phase 1/2 readout est. (NCT05024214)
DESCRIPTION:Envafolimab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: P
 hase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tu
 mors\nEstimated primary completion: December 2026. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/envafolimab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05024214
URL:https://assetmemo.bio/drug/envafolimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07003815-994@assetmemo.bio
DTSTAMP:20261121T004018Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Envafolimab: Phase 2 readout est. (NCT07003815)
DESCRIPTION:Envafolimab\, phase 2.\nStudy: Envafolimab With Chemotherapy an
 d Simvastatin in Advanced Biliary Tract Cancer\nEstimated primary completi
 on: December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/en
 vafolimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07003815
URL:https://assetmemo.bio/drug/envafolimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05112991-994@assetmemo.bio
DTSTAMP:20261121T004018Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Envafolimab: Phase 2 readout est. (NCT05112991)
DESCRIPTION:Envafolimab\, phase 2\, Endometrial Cancer.\nStudy: Study of En
 vafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial C
 ancer\nEstimated primary completion: December 2026. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/envafolimab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT05112991
URL:https://assetmemo.bio/drug/envafolimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05904015-994@assetmemo.bio
DTSTAMP:20261121T004018Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Envafolimab: Phase 2 readout est. (NCT05904015)
DESCRIPTION:Envafolimab\, phase 2.\nStudy: The Study of Envafolimab Combine
 d With Concurrent Chemoradiotherapy In LS-SCLC\nEstimated primary completi
 on: 30 December 2026. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /envafolimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT05904015
URL:https://assetmemo.bio/drug/envafolimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07243626-994@assetmemo.bio
DTSTAMP:20261121T004018Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Envafolimab: Phase 2 readout est. (NCT07243626)
DESCRIPTION:Envafolimab\, phase 2.\nStudy: Efficacy and Safety of Envafolim
 ab Plus Doxorubicin and Ifosfamide for Advanced Soft Tissue Sarcoma\nEstim
 ated primary completion: 30 December 2026. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/envafolimab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07243626
URL:https://assetmemo.bio/drug/envafolimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06321081-994@assetmemo.bio
DTSTAMP:20261121T004018Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Envafolimab: Phase 2 readout est. (NCT06321081)
DESCRIPTION:Envafolimab\, phase 2.\nStudy: ICE Study: Combination of Irinot
 ecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC\nEsti
 mated primary completion: 30 December 2026. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/envafolimab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06321081
URL:https://assetmemo.bio/drug/envafolimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05959356-994@assetmemo.bio
DTSTAMP:20261121T004018Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Envafolimab: Phase 2 readout est. (NCT05959356)
DESCRIPTION:Envafolimab\, phase 2.\nStudy: Cetuximab and Envafolimab Plus m
 FOLFOXIRI as First-line Treatment for RAS/BRAF Wild-type\, MSS\, Unresecta
 ble Left-side Metastatic Colorectal Cancer\nEstimated primary completion: 
 31 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/env
 afolimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT05959356
URL:https://assetmemo.bio/drug/envafolimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07852091-994@assetmemo.bio
DTSTAMP:20261121T004018Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Envafolimab: Phase 2 readout est. (NCT07852091)
DESCRIPTION:Envafolimab\, phase 2\, Chronic Hepatitis B.\nStudy: A Novel Co
 mbination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepat
 itis B Virus Infection (A)\nEstimated primary completion: 31 December 2026
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/envafolimab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07852091
URL:https://assetmemo.bio/drug/envafolimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07573943-994@assetmemo.bio
DTSTAMP:20261121T004018Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Envafolimab: Phase 4 readout est. (NCT07573943)
DESCRIPTION:Envafolimab\, phase 4\, Chronic Hepatitis B.\nStudy: ASC22 Comb
 ined With Peg-IFNa in Achieving Functional Cure in Patients With Chronic H
 epatitis B Virus Infection\nEstimated primary completion: 31 December 2026
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/envafolimab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07573943
URL:https://assetmemo.bio/drug/envafolimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07260305-994@assetmemo.bio
DTSTAMP:20261121T004018Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Envafolimab: Phase 1 readout est. (NCT07260305)
DESCRIPTION:Envafolimab\, phase 1.\nStudy: A Phase I Study to Investigate t
 he Safety and Tolerability of KGX101 Monotherapy and Combination Therapy W
 ith Envafolimab in Advanced or Metastatic Solid Tumor Patients\nEstimated 
 primary completion: 1 January 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/envafolimab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07260305
URL:https://assetmemo.bio/drug/envafolimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06059261-994@assetmemo.bio
DTSTAMP:20261121T004018Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Envafolimab: Phase 2 readout est. (NCT06059261)
DESCRIPTION:Envafolimab\, phase 2.\nStudy: Envafolimab Combined With Chemor
 adiotherapy and Recombinant Human Endostatin for LA-NPC.\nEstimated primar
 y completion: 1 February 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/envafolimab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06059261
URL:https://assetmemo.bio/drug/envafolimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07159191-994@assetmemo.bio
DTSTAMP:20261121T004018Z
DTSTART;VALUE=DATE:20270220
DTEND;VALUE=DATE:20270221
SUMMARY:Envafolimab: Phase 2 readout est. (NCT07159191)
DESCRIPTION:Envafolimab\, phase 2.\nStudy: Envafolimab Combined With Axitin
 ib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma
 \nEstimated primary completion: 20 February 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/envafolimab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07159191
URL:https://assetmemo.bio/drug/envafolimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06498622-994@assetmemo.bio
DTSTAMP:20261121T004018Z
DTSTART;VALUE=DATE:20270520
DTEND;VALUE=DATE:20270521
SUMMARY:Envafolimab: Phase 2 readout est. (NCT06498622)
DESCRIPTION:Envafolimab\, phase 2.\nStudy: Adjuvant Treatment of Patients W
 ith High Risk of Recurrent Hepatocellular Carcinoma With Donafenib in Comb
 ination With Envafolimab\nEstimated primary completion: 20 May 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/envafolimab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06498622
URL:https://assetmemo.bio/drug/envafolimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06663007-994@assetmemo.bio
DTSTAMP:20261121T004018Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Envafolimab: Phase 1/2 readout est. (NCT06663007)
DESCRIPTION:Envafolimab\, phase 1/2.\nStudy: RC48 Monotherapy or Combinatio
 n With Envafolimab for CDK12 Alterations mCRPC With Standard Treatment Fai
 lure\nEstimated primary completion: 31 May 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/envafolimab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06663007
URL:https://assetmemo.bio/drug/envafolimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05799469-994@assetmemo.bio
DTSTAMP:20261121T004018Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Envafolimab: Phase 2 readout est. (NCT05799469)
DESCRIPTION:Envafolimab\, phase 2.\nStudy: Study of Chemoradiotherapy With 
 Envafolimab For The Treatment of Locally Advanced Cervical Cancer\nEstimat
 ed primary completion: 31 May 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/envafolimab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT05799469
URL:https://assetmemo.bio/drug/envafolimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07559864-994@assetmemo.bio
DTSTAMP:20261121T004018Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Envafolimab: Phase 2 readout est. (NCT07559864)
DESCRIPTION:Envafolimab\, phase 2.\nStudy: Comparing Regorafenib Combined W
 ith Envafolimab to Physician's Choice in Patients With Metastatic Gastroin
 testinal Stromal Tumors Harboring KIT Exon 17 Mutations Refractory to Stan
 dard Treatment\nEstimated primary completion: 1 June 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/envafolimab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07559864
URL:https://assetmemo.bio/drug/envafolimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06734182-994@assetmemo.bio
DTSTAMP:20261121T004018Z
DTSTART;VALUE=DATE:20270622
DTEND;VALUE=DATE:20270623
SUMMARY:Envafolimab: Phase 2 readout est. (NCT06734182)
DESCRIPTION:Envafolimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Neo
 adjuvant Envafolimab Plus Disitamab Vedotin and Carboplatin in Resectable 
 HER2-Mutant Non-Small-Cell Lung Cancer\nEstimated primary completion: 22 J
 une 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/envafolimab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT067
 34182
URL:https://assetmemo.bio/drug/envafolimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06772233-994@assetmemo.bio
DTSTAMP:20261121T004018Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Envafolimab: Phase 2 readout est. (NCT06772233)
DESCRIPTION:Envafolimab\, phase 2.\nStudy: A Study of Regorafenib Combined 
 With Envafolimab for Metastatic Gastrointestinal Stromal Tumors With Kit G
 ene Exon 17 Mutation That Failed Standard Treatment\nEstimated primary com
 pletion: 30 July 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/envafolimab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06772233
URL:https://assetmemo.bio/drug/envafolimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04891198-994@assetmemo.bio
DTSTAMP:20261121T004018Z
DTSTART;VALUE=DATE:20270830
DTEND;VALUE=DATE:20270831
SUMMARY:Envafolimab: Phase 2 readout est. (NCT04891198)
DESCRIPTION:Envafolimab\, phase 2.\nStudy: ENVAFOLIMAB Single-agent Treatme
 nt in Patients With Advanced Solid Tumors\nEstimated primary completion: 3
 0 August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/envafo
 limab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT04891198
URL:https://assetmemo.bio/drug/envafolimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07256223-994@assetmemo.bio
DTSTAMP:20261121T004018Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Envafolimab: Phase 2 readout est. (NCT07256223)
DESCRIPTION:Envafolimab\, phase 2.\nStudy: A Clinical Trial of Envafolimab 
 Combined With Lenvatinib for Kidney Cancer With Liver Spread\nEstimated pr
 imary completion: 1 November 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/envafolimab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07256223
URL:https://assetmemo.bio/drug/envafolimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07729033-994@assetmemo.bio
DTSTAMP:20261121T004018Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Envafolimab: Phase 2 readout est. (NCT07729033)
DESCRIPTION:Envafolimab\, phase 2.\nStudy: A Phase II Exploratory Study of 
 Sacituzumab Tirumotecan Combined With Envafolimab for TROP2-Positive Advan
 ced Biliary Tract Cancers Previously Treated With First-Line Immunotherapy
  Combined With Chemotherapy.\nEstimated primary completion: December 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/envafolimab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07729033
URL:https://assetmemo.bio/drug/envafolimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06123754-994@assetmemo.bio
DTSTAMP:20261121T004018Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Envafolimab: Phase 3 readout est. (NCT06123754)
DESCRIPTION:Envafolimab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Pha
 se III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable
  Stage III NSCLC\nEstimated primary completion: 30 December 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/envafolimab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06123754
URL:https://assetmemo.bio/drug/envafolimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05969847-994@assetmemo.bio
DTSTAMP:20261121T004018Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Envafolimab: Phase 2 readout est. (NCT05969847)
DESCRIPTION:Envafolimab\, phase 2.\nStudy: Organ Preservation Following Env
 erolimab-based Total Neoadjuvant Therapy for Locally Advanced Very Low Rec
 tal Cancer\nEstimated primary completion: 31 December 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/envafolimab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT05969847
URL:https://assetmemo.bio/drug/envafolimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06692491-994@assetmemo.bio
DTSTAMP:20261121T004018Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Envafolimab: Phase 2 readout est. (NCT06692491)
DESCRIPTION:Envafolimab\, phase 2.\nStudy: Study of Precision Treatment for
  Rare Tumours in China Guided by PDO and NGS\nEstimated primary completion
 : 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/e
 nvafolimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06692491
URL:https://assetmemo.bio/drug/envafolimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07599995-994@assetmemo.bio
DTSTAMP:20261121T004018Z
DTSTART;VALUE=DATE:20280330
DTEND;VALUE=DATE:20280331
SUMMARY:Envafolimab: Phase 2 readout est. (NCT07599995)
DESCRIPTION:Envafolimab\, phase 2.\nStudy: Gemcitabine-Cisplatin Plus Envaf
 olimab in Resectable Biliary Tract Malignancies\nEstimated primary complet
 ion: 30 March 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/e
 nvafolimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07599995
URL:https://assetmemo.bio/drug/envafolimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07818304-994@assetmemo.bio
DTSTAMP:20261121T004018Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Envafolimab: Phase 2 readout est. (NCT07818304)
DESCRIPTION:Envafolimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: SRT
  Combined With Envafolimab and Endostar in the First-line Treatment of Adv
 anced NSCLC\nEstimated primary completion: April 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/envafolimab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07818304
URL:https://assetmemo.bio/drug/envafolimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06959693-994@assetmemo.bio
DTSTAMP:20261121T004018Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Envafolimab: Phase 2/3 readout est. (NCT06959693)
DESCRIPTION:Envafolimab\, phase 2/3.\nStudy: A Clinical Study to Evaluate t
 he Efficacy and Safety of Envafolimab Combined With Cetuxima-βand mFOLFOX
 6 in Patients With MSS\, RAS/BRAF Wild-Type Metastatic Colorectal Cancer (
 mCRC)\nEstimated primary completion: 30 September 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/envafolimab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06959693
URL:https://assetmemo.bio/drug/envafolimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07738055-994@assetmemo.bio
DTSTAMP:20261121T004018Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Envafolimab: Phase na readout est. (NCT07738055)
DESCRIPTION:Envafolimab\, phase na.\nStudy: Study on the Combined Treatment
  of Hepatocellular Carcinoma With Envafolimab\, Suvemcitug and HAIC Conver
 sion\nEstimated primary completion: 31 January 2029. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/envafolimab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07738055
URL:https://assetmemo.bio/drug/envafolimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07636798-994@assetmemo.bio
DTSTAMP:20261121T004018Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Envafolimab: Phase 1/2 readout est. (NCT07636798)
DESCRIPTION:Envafolimab\, phase 1/2.\nStudy: Hepatic Arterial Infusion Chem
 otherapy Plus Envafolimab and Lenvatinib for First-Line Unresectable Advan
 ced Biliary Tract Cancer\nEstimated primary completion: March 2029. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/envafolimab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07636798
URL:https://assetmemo.bio/drug/envafolimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04910386-994@assetmemo.bio
DTSTAMP:20261121T004018Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Envafolimab: Phase 2 readout est. (NCT04910386)
DESCRIPTION:Envafolimab\, phase 2.\nStudy: Multicenter Phase 2 Study of Env
 afolimab in Biliary Tract Cancers\nEstimated primary completion: June 2029
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/envafolimab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT04910386
URL:https://assetmemo.bio/drug/envafolimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06698965-994@assetmemo.bio
DTSTAMP:20261121T004018Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Envafolimab: Phase 2 readout est. (NCT06698965)
DESCRIPTION:Envafolimab\, phase 2.\nStudy: Efficacy and Safety of First-lin
 e Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination
  Therapy of Trilaciclib\, Envafolimab\, Etoposide\, and Carboplatin\nEstim
 ated primary completion: 31 October 2029. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/envafolimab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06698965
URL:https://assetmemo.bio/drug/envafolimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
